Helse og life science
Abelsen, B., Pedersen, K., Løyland, H. I., & Aandahl, E. (2023). Expanding general practice with interprofessional teams: a mixed-methods patient perspective study. BMC Health Services Research, 23(1), 1327.
Bjørk, M. H., Borkenhagen, S., Oteiza, F., Dueland, A. N., Sørgaard, F. E., Sæther, E. M., & Bugge, C. (2023). Comparative retention and effectiveness of migraine preventive treatments: A nationwide registry‐based cohort study. European Journal of Neurology.
Bråten, R. H., & Sten-Gahmberg, S. (2022). Unge uføre og veien til uføretrygd: The path to disability benefits for young people. Søkelys på arbeidslivet, 39(1), 1-19.
Bråten, R. H., Sten-Gahmberg, S., Bugge, C., Kristiansen I. S., Gardsjord, E. S. & Sæther, E. M. (2023). Økt bruk av psykiske diagnoser for unge. Tidsskrift for Norsk psykologforening.
Bugge, Christoffer, et al. (2018). Diagnosing heart failure with NT-proBNP point-of-care testing: lower costs and better outcomes. A decision analytic study. BJGP open 2(3), bjgpopen18X101596.
Bugge C, Brustugun OT, Sæther EM, Kristiansen IS (2021). Phase- and gender-specific, lifetime, and future costs of cancer: A retrospective population-based registry study. Medicine, 100(26), e26523. https://doi.org/10.1097/MD.0000000000026523.
Bugge, C., Kaasa, S., Sæther, E. M., Melberg, H. O., & Kristiansen, I. S. (2021). What are determinants of utilisation of pharmaceutical anticancer treatment during the last year of life in Norway? A retrospective registry study. BMJ open, 11(9), e050564.
Bugge C, Sæther EM, Kristiansen IS (2021). Men receive more end-of-life cancer hospital treatment than women: fact or fiction?. Acta Oncologica. doi: 10.1080/0284186X.2021.1917000 (Accepted for publication April 2021).
Bugge C, Sæther EM, Brustugun OT, Kristiansen IS (2021). Societal cost of cancer in Norway – Results of taking a broader cost perspective. Health Policy. 2021 May 24;S0168-8510(21)00135-4. doi: 10.1016/j.healthpol.2021.05.008.
Engebretsen, I., Bugge, C., Støvring, H., Husebye, E., Sverre, E., Dammen, T., Halvorsen, S & Munkhaugen, J. (2024). Treatment patterns and adherence to lipid-lowering drugs during eight-year follow-up after a coronary heart disease event. Atherosclerosis, https://doi.org/10.1016/j.atherosclerosis.2024.117550.
Engebretsen, I., Munkhaugen, J., Bugge, C., Halvorsen, S., Ødegaard, K. M., Støvring, H., & Kristiansen, I. S. (2022). Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs. European Heart Journal Open, 2(6), oeac070.
Engebretsen, I., Gilhus, N. E., Kristiansen, I. S., Sæther, E. M., Lindberg‐Schager, I., Arneberg, F., & Bugge, C. (2024). The epidemiology and societal costs of myasthenia gravis in Norway: A non‐interventional study using national registry data. European Journal of Neurology, e16233.
Hindhammer, A., Ali, Z., Lange, M., Pedersen, S.H., Steinland, E., Sæther, E.M., Sørbråten, T. (2012). Gir innføring av multidose riktigere legemiddelbruk? Norsk Farmasøytisk tidsskrift 4/2012.
Hovland R, Bremer S, Frigaard C, Henjum S, Faksvåg PK, Sæther EM and Kristiansen IS (2020). Effect of a pharmacist-led intervention on adherence among patients with a first-time prescription for a cardiovascular medicine: a randomized controlled trial in Norwegian pharmacies. International Journal of Pharmacy Practice.
Yngvil Solheim Husum, Ragnhild Haugli Bråten, Erik Magnus Sæther, Morten Carstens Moe, Ivar Sønbø Kristiansen, Øystein Kalsnes Jørstad (kommer i 2024). Intravitreal anti-vascular endothelial growth factor therapy for retinal diseases in Norway from 2011 to 2021: A combined registry and survey study. Acta Ophthalmologica.
I. S. Kristiansen, R. H. Bråten, Ø. K. Jørstad, M. C. Moe og E. M. Sæther (2019). Intravitreal therapy for retinal diseases in Norway 2011–2015. Acta Ophthalmologica. doi: 10.1111/aos.14262
Kristiansen IS, Bugge C (2018). Prioritering i pasienters siste leveår. Tidsskriftet Den Norske Legeforening.
Kristiansen IS, Bugge C, Forde OH (2018). Bidrar overdiagnostikk til høye melanomtall? Tidsskriftet Den Norske Legeforening.
Løyland, H. I., Pedersen, K., Sten-Gahmberg, S., Harsheim, I. G., Sæther, E. M., Iversen, T., … & Abelsen, B. (2023). Effekter, gevinster og kostnader ved digital hjemmeoppfølging – en samfunnsøkonomisk analyse basert på et pragmatisk randomisert forsøk. Magma, 26(5).
Nyen, J. E., Booth, A. Ø., Huseby, Ø., Bugge, C., Engebretsen, I., Oteiza, F., Helland, Å., Fjellbirkeland, L., Brustugun, O. T. & Grønberg, B. H. (2025). Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study. Front. Oncol. 15:1506041. doi: 10.3389/fonc.2025.1506041
Oteiza F, Løyland HI, Bugge C, Kristiansen IS, Støvring H (2021). Persistence of statin treatment – the impact of analytic method when estimating drug survival. Norsk Epidemiologi 2021; 29.
Pedersen, K., Løyland, H. I., Sæther, E. M., Sten-Gahmberg, S., Abelsen, B., Snilsberg, Ø., & Iversen, T. (2023). Primærhelseteam – en mer teambasert fastlegetjeneste. Magma, 26(5).
Sten-Gahmberg, S., Pedersen, K., Harsheim, I.G. et al. Experiences with telemedicine-based follow-up of chronic conditions: the views of patients and health personnel enrolled in a pragmatic randomized controlled trial. BMC Health Serv Res 24, 341 (2024).
Sten-Gahmberg, S., Pedersen, K., Harsheim, I.G. et al. Pragmatic randomized controlled trial comparing a complex telemedicine-based intervention with usual care in patients with chronic conditions. Eur J Health Econ (2024).
Sæther EM, Bugge C, Kristiansen IS (2017). Den nye virkeligheten. Overlegen 2-2017:26-7.
Sæther EM, Løyland HI, Bugge C (2022). An economic analysis indicates less strict infection control of COVID-19. Tidsskriftet Den Norske Legeforening.
Torkki, P., Leskelä, R. L., Bugge, C., Torfadottir, J. E., & Karjalainen, S. (2022). Cancer-related costs should be allocated in a comparable way—benchmarking costs of cancer in Nordic countries 2012–2017. Acta Oncologica, 61(10), 1216-1222.
Du finner mer informasjon om vårt arbeid innenfor helse og life science på denne siden.
Konkurranse, marked og regulering
Asphjell, M. K., Bergh, H. N., Merker, T., & Skaar, J. (2017). Unilateral effects of horizontal mergers with vertical relations between firms and other structural market changes. Review of Industrial Organization, 51(3), 381-394.
Bergh, H.N., Gramstad, A.R. & Skaar, J. (2020). Unilateral Price Effects and Vertical Relations Between Merging and Non-merging Firms. Review of Industrial Organization. 57(1) 131-143.
Bergh, H. N.; Hammersmark, E. M.; Hansen, J. S.; Skaar, J. (2020). Samfunnsøkonomiske konsekvenser av et forbud mot prisdiskriminering i det norske dagligvaremarkedet. Samfunnsøkonomen, 136(1), ss. 4-11.
Braunfels E, Gramstad A, Skaar J (2019). Efficiency Gains vs. Internalization of Rivalry: Brand-Level Evidence from a Merger in the Mobile Telecom Market.
Evensen, C.B., Steen, F., & Ulsaker, S.A. (2023). Co-location, good, bad or both: How do new entries of discount variety stores affect local grocery businesses?, Journal of the European Economic Association
Du finner mer informasjon om vårt arbeid innenfor konkurranse, marked og regulering på denne siden.
Kultur, idrett og medier
Skille EÅ, Hanstad DV, Svensgaard M, Lien G, Bugge C (2021). Lokale aktivitetsmidler – Implementering av den statlige idrettspolitikken. Norsk sosiologisk tidsskrift04 / 2021 (Volum 5).
Du finner mer informasjon om vårt arbeid innenfor kultur, idrett og medier på denne siden.
Ressurser og bærekraft
Aragón, F. M., Oteiza, F., & Rud, J. P. (2021). Climate change and agriculture: Subsistence farmers’ response to extreme heat. American Economic Journal: Economic Policy, 13(1), 1-35.
Arin, P.; & Braunfels, E. (2018). The Resource Curse Revisited: A Bayesian Approach Model Averaging Approach. Energy Economics, vol. 70(C), pages 170-178.
Du finner mer informasjon om vårt arbeid innenfor ressurser og bærekraft på denne siden.
Utviklingsøkonomi
Abramovsky, L., Augsburg, B., Lührmann, M., Oteiza, F., & Rud, J. P. (2023). Community matters: Heterogeneous impacts of a sanitation intervention. World Development, 165, 106197.
